hotspot -WSS

hotspot

author：focus 2025-09-29 22:53:54 - browse：28

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Colonoscopy prep: Liquid

knowledge

hotspot

WSS

Readout Newsletter: Bluebird, CVS, Contineum

How climate

Argenx readies a blockbuster opportunity with drug for autoimmune disease

STAT Summit: How a Chicago ER doctor tackles gun violence

Neuroscience’s long legacy of racism

FDA warns J&J's Abiomed: We will regulate your software

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Hollywood unions extend contract negotiations for actors

Hospital price transparency does save money, advocate argues

Bright Health sells Medicare Advantage business to Molina

The EU Joint Clinical Assessment needs to live up to its promise

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: Bluebird, CVS, Contineum

BioMarin wins approval for gene therapy to treat hemophilia A

Colonoscopy prep: Liquid

hotspot

FDA gives detailed accounting of AI

Impact of Dobbs ruling felt at reproductive medicine meeting

Hospital price transparency does save money, advocate argues

Stop the failed accountable care organization experiment

CEOs share strategies for surviving biotech slump

U.K. researchers warn about biases in medical devices, algorithms

knowledge

leisure time

hotspot

Wikipedia